Seaport Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed Jun 8, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed Jun 8, 2026

SPTX$21.93+2.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)(Unaudited)

	March 31,	December 31,
	2026	2025
Assets
Current assets:
Cash and cash equivalents	$52,909	$46,042
Short-term investments	129,696	169,941
Prepaid expenses and other current assets	5,736	7,247
Total current assets	188,341	223,230
Property and equipment, net	386	412
Right-of-use assets - operating leases	5,066	4,813
Long-term investments	30,037	17,670
Other non-current assets	3,843	2,884
Total assets	$227,673	$249,009
Liabilities, convertible preferred stock and stockholders' deficit
Current liabilities:
Accounts payable	$4,787	$2,007
Related party payable	11	7
Accrued expenses and other current liabilities	7,826	9,131
Operating lease liability	1,599	1,637
Total current liabilities	14,223	12,782
Operating lease liability, net of current portion	3,743	3,444
Total liabilities	17,966	16,226
Commitments and contingencies (Note 14)
Series A-1 convertible preferred stock, par value $0.0001; 40,000,000 shares authorized, issued, and outstanding; liquidation preference of $4,000 as of March 31, 2026 and December 31, 2025	—	—
Series A-2 convertible preferred stock, par value $0.0001; 26,342,102 shares authorized, issued, and outstanding; liquidation preference of $100,100 as of March 31, 2026 and December 31, 2025	99,757	99,757
Series B convertible preferred stock, par value $0.0001; 47,578,938 shares authorized; 47,578,934 shares issued and outstanding; liquidation preference of $226,000 as of March 31, 2026 and December 31, 2025	225,571	225,571
Stockholders' deficit
Common stock, par value $0.0001; 159,070,000 shares authorized; 2,595,342 and 2,594,960 shares issued and outstanding as of March 31, 2026 and December 31, 2025 respectively	1	1
Cumulative translation adjustment	—	—
Additional paid-in capital	23,831	21,262
Accumulated other comprehensive income	64	301
Accumulated deficit	(139,517)	(114,109)
Total stockholders' deficit	(115,621)	(92,545)
Total liabilities, convertible preferred stock and stockholders' deficit	$227,673	$249,009

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts) (Unaudited)

	Three Months Ended March 31,
	2026	2025
Operating expenses:
Research and development (including stock-based compensation expense of $0.9 million and $0.5 million for three months ended March 31, 2026 and 2025, respectively)	$21,431	$10,534
General and administrative (including stock-based compensation expense of $1.7 million and $1.1 million for the three months ended March 31, 2026 and 2025, respectively)	6,112	5,651
Total operating expenses	27,543	16,185
Loss from operations	(27,543)	(16,185)
Other income (expense), net
Interest income, net	2,133	3,100
Research and development tax credit	567	—
Other expense, net	(46)	(9)
Total other income, net	2,654	3,091
Loss before income taxes	(24,889)	(13,094)
Income tax provision	519	31
Net loss	$(25,408)	$(13,125)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	15	—
Unrealized (loss) gain on available-for-sale securities	(252)	192
Comprehensive loss	$(25,645)	$(12,933)
Net loss per share, basic and diluted	$(10.34)	$(5.65)
Weighted-average common shares outstanding, basic and diluted	2,456,766	2,323,724

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.